France-based Nicox SA, an opthalmology company, has appointed Gavin Spencer as chief executive officer. Dr Spencer is a long-standing executive at Nicox, joining the company in 2005, and has been involved in all aspects of its business, most recently as chief business officer and head of corporate development. His initial focus as CEO will be on enabling Nicox to generate the additional data to make a new drug application for Nicox’s lead asset NCX 470, Denali.
Dr Spencer holds a PhD in chemistry from the University of Aberdeen, UK.
Nicox announced the appointment on 28 February 2024.
Copyright 2024 Evernow Publishing Ltd